Star Combo Pharma Ltd

Star Combo Pharma maintains a strong liquidity position, with a current ratio of 4.4 and cash and equivalents amounting to AUD 18,110,940. The company's debt-to-equity ratio is 0.1, indicating a conservative capital structure with minimal leverage. Free cash flow stands at AUD 6,265,880, supporting operational flexibility and potential reinvestment [doc:HA-latest]. Profitability metrics show a return on equity of 13.78% and a return on assets of 10.83%, both exceeding the typical thresholds for the Retailers sector. The company's operating income of AUD 5,429,010 and net income of AUD 5,248,660 reflect strong performance relative to its revenue of AUD 28,240,120 [doc:HA-latest]. The company operates through two segments: the Star Combo business and the Austoyou retail business. The Austoyou segment focuses on an Australia-China e-commerce platform, offering over 5,000 product lines directly to Chinese consumers. Revenue concentration data is not provided, but the dual-segment model suggests diversification across product development and direct-to-consumer retail [doc:HA-latest]. Growth trajectory is supported by a strong operating cash flow of AUD 11,941,720 and a capital expenditure of -AUD 393,720, indicating efficient capital use. The outlook for the current fiscal year shows a positive direction, with revenue and profitability expected to maintain their upward trend [doc:HA-latest]. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and high cash reserves reduce financial risk exposure. No dilution pressure is expected in the near term, with no recent issuance or shelf registration activity reported [doc:HA-latest]. Recent events include the continued expansion of the Austoyou e-commerce platform and the development of new product lines under the Costar, Living Healthy, Amax, and J&K brands. The company's OEM services and quality assurance offerings also contribute to its competitive positioning [doc:HA-latest].